2025-2034 Acute Care Syndromic Testing Market Outlook: Key Drivers, Emerging Challenges, and Strategic Insights

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Acute Care Syndromic Testing Industry Market Size Be by 2025?
The market size for acute care syndromic testing has experienced remarkable growth in recent times. The market, which was valued at $4.08 billion in 2024, is projected to increase to $4.59 billion in 2025, with a compound annual growth rate (CAGR) of 12.3%. Factors driving this growth during the historic period include heightened awareness of antimicrobial resistance, an upsurge in government spending on infectious diseases, escalated investment in the healthcare structure, a growing emphasis on syndromic testing, the broadening of telemedicine, and an increase in the prevalence of infectious diseases.

What's the Long-Term Growth Forecast for the Acute Care Syndromic Testing Market Size Through 2029?
The syndromic testing market for acute care is anticipated to expand significantly in the coming years, reaching a value of $7.39 billion in 2029 with a compound annual growth rate (CAGR) of 12.7%. This growth over the projected period can be linked to several factors such as increased instances of infectious diseases, higher demand for rapid diagnostic solutions, enhancement in healthcare services, the increasing application of multiplex syndromic panels, and a growing elderly population. Crucial trends predicted during the forecast period encompass the transition towards point-of-care testing, incorporation of cloud-based platforms, utilization of multiplex panels, the emergence of AI-powered tools, and the automation of syndromic testing.

View the full report here:
https://www.thebusinessresearchcompany.com/report/acute-care-syndromic-testing-global-market-report

What Are the Key Growth Drivers Fueling the Acute Care Syndromic Testing Market Expansion?
The escalation in the prevalence of infectious diseases is anticipated to boost the acute care syndromic testing market in the future. The rise of such diseases, prompted by detrimental microorganisms like bacteria, viruses, fungi, or parasites, escalates the need for effective prevention and treatment. These diseases can transmit among individuals, from animals, or the environment, and their prevalence is driven by elements like population growth, urbanization, international travel, resistance to antibiotics, and climate alteration. Acute care syndromic testing is employed in the identification of infectious ailments to hastily pinpoint pathogens and co-infections using multiplex molecular diagnostics, which facilitates targeted treatment protocols. For example, the UK based government organization, Health Security Agency, reported in February 2024 that the positivity rate of influenza exponentially rose to 16.6% in the fourth week of 2024, an increase from 14.0% the preceding week. Along with this, consultations related to Influenza-like illness (ILI) also climbed, reaching 9.8 per 100,000 people, as opposed to 7.5 per 100,000 the previous week. Furthermore, Influenza-related hospital admissions also escalated to 7.63 per 100,000, up from 5.12 per 100,000 the prior week. Hence, the ascending prevalence of infectious diseases is propelling the acute care syndromic testing market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21078&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Acute Care Syndromic Testing Market?
Leading corporations in the acute care syndromic testing market are prioritizing technological improvements such as multiplex real-time polymerase chain reaction (PCR) technology to upgrade diagnostic precision, expedite pathogen identification, simplify laboratory processes, reduce response time, and enhance patient results via accurate and prompt treatment procedures. Multiplex real-time PCR technology, a sophisticated molecular diagnostic technique can simultaneously detect and measure multiple pathogens or genetic targets in a singular PCR reaction, thereby enhancing efficiency and precision in diagnosing diseases. To illustrate, in April 2023, QIAGEN N.V., a biotech research firm from the Netherlands, introduced QIAstat-Dx, a syndromic testing solution in Japan. This system includes a SARS-CoV-2 respiratory panel capable of detecting beyond 20 pathogens from a single specimen. Utilizing multiplex real-time PCR technology, it generates swift results with less labor compared to individual PCR tests. By the close of 2022, over 3,500 systems had been installed worldwide to aid in diagnosing respiratory, gastrointestinal, and meningitis-related issues. The system is accessible in more than 100 countries, thereby promoting global syndromic testing accessibility.

How Is the Acute Care Syndromic Testing Market Segmented?
The acute care syndromic testing market covered in this report is segmented -

1) By Disease Type: Respiratory Diseases, Gastrointestinal Diseases, Genitourinary Diseases, Tropical Diseases, Other Disease Types
2) By Sample Type: Blood, Urine, Biofluids, Stool, Swabs, Other Sample Types
3) By Target: Bacteria, Viruses, Fungi, Parasites
4) By End User: Hospitals, Clinical And Diagnostic Laboratories, Research And Academic Institutions, Other End Users

Subsegments:
1) By Respiratory Diseases: Influenza, Respiratory Syncytial Virus (RSV), COVID-19, Tuberculosis, Other Respiratory Diseases
2) By Gastrointestinal Diseases: Clostridium Difficile Infection, Norovirus, Rotavirus, Salmonella, Other Gastrointestinal Diseases
3) By Genitourinary Diseases: Urinary Tract Infections (UTIs), Sexually Transmitted Infections (STIs), Vaginal Infections, Other Genitourinary Diseases
4) By Tropical Diseases: Malaria, Dengue, Chikungunya, Zika Virus, Other Tropical Diseases
5) By Other Disease Types: Meningitis, Sepsis, Other Emerging Infectious Diseases

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=21078&type=smp

Which Companies Are Leading the Charge in Acute Care Syndromic Testing Market Innovation?
Major companies operating in the acute care syndromic testing market are Siemens Healthineers AG, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Danaher Corporation, Becton, Dickinson and Company, Seegene Inc., bioMérieux SA, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Werfen, DiaSorin S.p.A., Quidel Corporation, Luminex Corporation, Biocartis NV, Microbiologics Inc., QuantuMDx Group Ltd., Curetis GmbH by OpGen Inc., Genetic Signatures Ltd., Applied BioCode Inc.

Which Regions Are Leading the Global Acute Care Syndromic Testing Market in Revenue?
North America was the largest region in the acute care syndromic testing market in 2024. The regions covered in the acute care syndromic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21078

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.